Multiple Sclerosis Clinical Trials

It depends on the trial. Some trials allow concurrent DMTs, particularly those studying add-on therapies or symptom management. Others require a washout period from your current DMT before starting the investigational treatment. The washout requirements and timing vary based on which medication you are currently taking and the trial protocol.

Yes. There is a growing number of trials focused on primary progressive MS (PPMS) and secondary progressive MS (SPMS). These trials test BTK inhibitors, neuroprotective agents, remyelination therapies, and combination approaches. Progressive MS trials are a high priority for the research community because effective treatments remain limited.

Most MS trials include MRI scans at screening, baseline, and then every 3 to 6 months during the treatment period. Some trials require more frequent scanning in the early months. These scans are covered by the trial sponsor and use advanced protocols that may detect changes not visible on routine clinical MRI.

Remyelination trials test drugs that aim to repair the protective myelin coating around nerves that is damaged in MS. Unlike current DMTs that reduce inflammation, remyelination therapies could potentially restore lost function. These trials typically measure outcomes using specialized MRI, visual evoked potentials, and functional assessments over 6 to 12 months or longer.